CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
WESTON, Fla., May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Cantex's azeliragon, a well-tolerated once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products), will be featured in four abstracts at this year's 2024 ASCO Annual Meeting to be held in Chicago.
佛羅里達州韋斯頓，2024年5月28日 /PRNewswire/ — Cantex Pharmicals, Inc. 是一家臨床階段的製藥公司，專注於爲癌症和其他急需新療法的危及生命的疾病開發變革性療法。該公司今天宣佈，Cantex的azeliragon是一種耐受性良好的每日一次藥丸，將推出四種藥丸今年將在芝加哥舉行的2024年ASCO年會的摘要。
"The 2024 ASCO Annual Meeting represents an important opportunity to meet with the leading oncology researchers from around the world and showcase the progress of azeliragon clinical investigations at leading cancer centers in several difficult-to-treat cancers," said Stephen G. Marcus, M.D., Cantex's Chief Executive Officer.
Cantex首席執行官斯蒂芬·馬庫斯醫學博士表示：“2024年ASCO年會是一個重要的機會，可以與來自世界各地的領先腫瘤研究人員會面，展示azeliragon在主要癌症中心對幾種難以治療的癌症進行臨床研究的進展。”
2024 ASCO Annual Meeting Abstracts:
2024 年 ASCO 年會摘要：
Title: A phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.
Abstract #: TPS4212
標題： 一項I/II期開放標籤研究，旨在評估azeliragon對轉移性胰腺癌一線治療難治的患者的安全性和初步證據。
摘要 #: TPS4212
Title: Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial design.
Abstract #: TPS2096
標題： RAGE 抑制劑 Azeliragon 與替莫唑胺聯合放射療法治療新診斷的膠質母細胞瘤患者：Ib/II 期 CAN-201 NDG 試驗設計。
摘要 #: TPS2096
Title: RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE).
Abstract #: TPS619
標題： 抑制 RAGE 可降低早期乳腺癌 (RAGE) 女性與癌症治療相關的心臟毒性。
摘要 #: TPS619
Title: A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION).
Abstract #: TPS2093
標題： 一項I/II期研究，旨在評估azeliragon聯合立體定向放射療法對腦轉移患者（ADORIATION）具有治療作用的安全性和初步證據。
摘要 #: TPS2093
About Azeliragon
關於 Azeliragon
Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products (known as RAGE) with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment. Azeliragon was discovered by and originally under development for Alzheimer's disease by vTv Therapeutics Inc. (NASDAQ: VTVT) from which Cantex licensed worldwide rights to azeliragon. Clinical safety data from these trials, involving more than 2000 individuals dosed for periods up to 18 months, indicate that azeliragon is very well tolerated.
Azeliragon 是一種口服膠囊，每天服用一次，可抑制晚期糖化終產物（稱爲 RAGE）受體與某些配體（包括 HMGB1 和 S100 蛋白）的相互作用，包括腫瘤微環境中的和 S100 蛋白。Azeliragon是由vTV Therapeutics Inc.（納斯達克股票代碼：VTVT）發現並最初正在開發用於阿爾茨海默氏病的開發中，Cantex從該公司獲得了阿澤利拉貢的全球版權。這些試驗的臨床安全性數據表明，azeliragon的耐受性非常好，涉及2000多名患者，給藥時間長達18個月。
Cantex has ongoing Phase II clinical trials in pancreatic cancer, glioblastoma, brain metastasis, breast cancer, and a Phase 3 trial in hospitalized patients with pneumonia to prevent acute kidney injury. These trials are based on azeliragon's robust preclinical data as well as its extensive clinical safety information from randomized placebo-controlled clinical trials.
Cantex正在進行胰腺癌、膠質母細胞瘤、腦轉移、乳腺癌的II期臨床試驗，以及一項針對肺炎住院患者的3期臨床試驗，以預防急性腎損傷。這些試驗基於azeliragon強大的臨床前數據及其來自隨機安慰劑對照臨床試驗的大量臨床安全性信息。
Azeliragon has U.S. Food and Drug Administration (FDA) orphan drug designation for the treatment of pancreatic cancer and glioblastoma. FDA Orphan Drug Designation provides Cantex with seven years of azeliragon marketing exclusivity from the time of product launch for the orphan indication, and several other important benefits, including assistance in the drug development process, tax credits for clinical costs, and exemptions from certain FDA fees.
Azeliragon 被美國食品藥品監督管理局 (FDA) 認定爲用於治療胰腺癌和膠質母細胞瘤的孤兒藥。FDA孤兒藥認證爲Cantex提供了自孤兒適應症產品發佈之日起七年的azeliragon獨家上市權，以及其他幾項重要好處，包括藥物開發過程中的援助、臨床成本的稅收抵免以及某些FDA費用的豁免。
About Cantex Pharmaceuticals, Inc.
關於 Cantex 製藥公司
Cantex Pharmaceuticals, Inc. is a privately held, clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed. To learn more please visit .
Cantex Pharmaceuticals, Inc. 是一傢俬人控股的臨床階段製藥公司，專注於爲癌症和其他急需新療法的危及生命的疾病開發變革性療法。要了解更多信息，請訪問 。
About vTv Therapeutics Inc.
關於 vTV Therapeutics Inc.
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates, led by cadisegliatin (TTP399), a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients. To learn more please visit vtvtherapeutics.com.
vTV Therapeutics Inc. 是一家臨床階段的生物製藥公司，專注於開發口服小分子候選藥物，由 cadisegliatin (TTP399)，一種潛在的變革性療法，可減少1型糖尿病患者的低血糖發作。要了解更多信息，請訪問 vtvtherapeutics.com。
Contact Information:
聯繫信息：
Cantex Pharmaceuticals, Inc.
Cantex 製藥有限公司
Stephen G. Marcus, M.D.
+1 954-315-3660
[email protected]
斯蒂芬·G·馬庫斯，醫學博士
+1 954-315-3660
[電子郵件保護]
Juan F. Rodriguez
+1 954-315-3660
[email protected]
胡安·羅德里格斯
+1 954-315-3660
[電子郵件保護]
Tiberend Strategic Advisors, Inc.
Tiberend 戰略顧問有限公司
Investors
Daniel Kontoh-Boateng
+1 862-213-1398
[email protected]
投資者
Daniel Kontoh-Boateng
+1 862-213-1398
[電子郵件保護]
Media
Casey McDonald
+1 646-577-8520
[email protected]
媒體
凱西·麥克唐納
+1 646-577-8520
[電子郵件保護]
SOURCE Cantex Pharmaceuticals, Inc.
來源 Cantex 製藥公司
譯文內容由第三人軟體翻譯。